	Summary of Informed Consent (IC) Audits	
	Conducted Q4 FY 2019	
(note: numbers in blue italics are from the 2017 IC audit)		
72 (80) protocols reviewed 32 (14) non-IND treatment 40 (66) observational	• 197 (95) enrolled in non-IND treatment protocols • QI acti	Il improvement compared to 2017 audit. ivities after 2017 audit included: team-based and development of CCR Informed Consent SOP
Overall Findings	 14 protocols (19%): no deficiencies found; 2 (2.2%); Improved 27 protocols (37.5%): no issues reportable to the IRB; 3 (3.8%); Improved 31 protocols (43%): at least one finding was reportable to the IRB; 75 (93.75%); Improved 	
Finding	Detailed Findings	
Several findings are ≤ 4%	 Correct version of consent not used (n=5, <1%); 2%; Improved IC document not in CRIS (n=1, <1%); No change Investigator signature missing (n=1, <1%); None IC obtain by someone not listed on the KSP or delegated to consent (n=23, 4%); 2%: worse than previous Inconsistent dates (n=8, <2%); 4%; Improved Not all embedded questions answered if applicable (4 out of 14, <1%); 2%; Improved Extraneous marks on IC document (n=18, 3%); 5%; Improved No IC note in CRIS (n=24, 4%); 23%; Improved 	
Inadequate documentation of IC process (10%); 13% - Improved	 Applies to 57 records. CRIS note doesn't specify that the patient received a copy of the IC document (2%); 1%, worse than previous IC process documentation greater than 72 hours (CCR SOP) (8%); 6% when measured at one month Missing interpreter name/code in CRIS note (n=3, 9%); collected with other required note elements NIH admin section on short form missing (n=4, 15%); N/A per policy CRIS note missing assent process (n=5, 18%); >50%; Improved 	
For assent process, missing signature/date on IC document or assent document (11%); not collected separately		